The Arbutus Story Isn't The Recent Win Over Moderna

About: Arbutus Biopharma Corporation (ABUS), Includes: BNTX, ECOR, MRNA
by: StockMatusow
This article is exclusive for subscribers.
Long/Short Equity, Deep Value, Value, Research Analyst

The biotech sector in the stock market has been on fire lately.

Stocks that are involved with potential COVID-19 vaccinations have gone on a big run, with a few gaining over 1,000%.

In this write-up, we focus on a company that has been getting a lot of attention lately, but not for the reasons we think it should.

The company has substantial catalysts in the near term that, we think, make it a good long trade and a speculative investment for certain risk-averse investors.

Written by Scott Matusow and Danny Cohen

There's been a lot of hype on Arbutus (NASDAQ:ABUS) as of late. The company recently successfully beat back a challenge to their general Intellectual Property (IP)